Twist Bioscience Corporation
TWST
Rang in Aktien
#2194
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Aktienkurs
$140.67
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$9.26B
Veränderung (1 Tag)
5.97%
Veränderung (1 Jahr)
329.66%
Land
US
Handel Twist Bioscience Corporation (TWST)
Kategorie
Healthcare
Gewinn für Twist Bioscience Corporation (TWST)
Gewinn im Jun 2026 TTM: $-135.85M
Laut den aktuellen Finanzberichten von Twist Bioscience Corporation betragen die aktuellen Gewinne des Unternehmens $-135.85M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $-208.17M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $-203.47M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Twist Bioscience Corporation von 2016 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-135.85M | 76.55% |
| 2025 | $-76.95M | -63.03% |
| 2024 | $-208.17M | 2.31% |
| 2023 | $-203.47M | -10.87% |
| 2022 | $-228.27M | 48.20% |
| 2021 | $-154.03M | 10.38% |
| 2020 | $-139.55M | 29.96% |
| 2019 | $-107.38M | 51.25% |
| 2018 | $-70.99M | 20.27% |
| 2017 | $-59.03M | 33.89% |
| 2016 | $-44.09M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $7.61B | -5,700.87% |
US
|
|
| $4.76B | -3,605.23% |
US
|
|
| $-252.70M | 86.01% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,320.43% |
US
|
